Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Study to Learn About the Study Medicine Called Ritlecitinib in People With Hives Without a Known Cause Recruiting

2025-522642-44-00 CHRONIC SPONTANEOUS URTICARIA 4 2026-03-18
BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to suppo… Recruiting

2023-508116-32-00 Antibody-mediated rejection of renal grafts 4 2026-03-17
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm… Recruiting

2025-523306-33-00 Idiopathic Nephrotic Syndrome 4 2026-03-12
Changes in the wound microbiome and their impact on chronic wound healing under hyperbaric conditions Recruiting

2025-523863-39-00 chronic wounds 6 2026-03-05
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab ( Switch-Up ) Recruiting

2025-523347-35-00 Atopic Dermatitis 11 2026-03-05
CLonE-specific CAR T-Cell therapy in relapsed or refractory AL amyloidosis - a single-center Phase I trial (CLEAR AL) Recruiting

2025-520790-39-00 relapsed or refractory AL amyloidosis 3 2026-03-04
A Trial of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE) Recruiting

2025-521742-15-00 Treatment of Late Isolated Microvascular Inflammation i 4 2026-03-03
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting

2025-521035-37-00 Immune system diseases 5 2026-03-02
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard… Recruiting

2025-521634-29-00 Acute Myeloid Leukemia 5 2026-03-02
An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with activ… Recruiting

2025-522853-21-01 Active, treatment refractory, ANCA-IgG-positive associa 9 2026-02-27
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic … Recruiting

2025-523826-41-00 Dermatitis atopic 1 2026-02-25
INFINITY - Effect of interferon gamma as a treatment for post-aggressive immunosuppression in intensive care units, a randomized Bayesian do… Recruiting

2023-506725-11-00 Post-aggressive immunosuppression 5 2026-02-24
A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004) Recruiting

2025-523412-36-00 Systemic lupus erythematosus, Rheumatoid arthritis 3 2026-02-17
A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host… Recruiting

2025-521849-25-00 Chronic Graft-Versus-Host Disease 4 2026-02-17
Single and multiple ascending dose of ZP9830 in healthy participants Recruiting

2023-509929-51-00 Autoimmune diseases 1 2026-02-10
Leniolisib OLE for Immune Dysregulation in PID Recruiting

2025-522444-40-00 primary immunodeficiency 4 2026-02-10
A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers. Recruiting

2025-523328-31-00 Inflammatory diseases 1 2026-02-06
Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i… Recruiting

2023-508611-22-00 systemic lupus 4 2026-02-03
A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious… Recruiting

2023-508930-33-00 Non-infectious active cryoglobulinemia vasculitis who a 4 2026-01-30
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE… Recruiting

2025-521802-17-00 Erosive/inflammatory osteoarthritis of the hands 5 2026-01-30
NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting

2023-510253-42-00 Adult patients aged 18 and over with unicentric hyalino 4 2026-01-28
FT819 in B-cell Mediated Autoimmune Diseases Recruiting

2024-517397-25-00 B-cell Mediated Autoimmune Diseases 1 2026-01-26
Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting

2025-522333-61-00 Hidradenitis suppurativa 4 2026-01-23
An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in pat… Recruiting

2025-522857-20-00 Severe, treatment refractory primary Sjögren’s disease 9 2026-01-22